Back to top

LACOG 0821 – AMIGO-1

  /    /  LACOG 0821 – AMIGO-1

A single arm, phase 2 study of amivantamab, lazertinib and pemetrexed for first-line treatment of recurrent / metastatic non-small cell lung cancers (NSCLCs) with EGFR mutations

Type of Study: Clinical Trial

Sponsor / Support: LACOG, Janssen

Primary Objectives: To evaluate the 18-month progression-free survival (PFS) rate of amivantamab, lazertinib and pemetrexed for first-line treatment of recurrent / metastatic non-small cell lung cancers (NSCLCs) with EGFR mutations.

Design: Interventional, single-arm, phase II trial  

Sample Size: 49 patients.

Principal Investigator: William Nassib William Junior

Countries LATAM: Brazil

Clinicaltrials.gov Identifier: NCT05299125

Download the study poster presented at the 2023 ESMO Congress here:

The study is open to patients participation in the following research sites:

Hospital de Amor / Barretos / SP / Brazil

Irmandade da Santa Casa de Misericórdia de Porto Alegre / Porto Alegre / RS / Brazil

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto USP / Ribeirão Preto / SP / Brazil

Hospital Evangélico de Cachoeiro do Itapemirim / Cachoeiro de Itapemirim / ES / Brazil

Pronutrir / Fortaleza / CE / Brazil

ICESP - Instituto de Câncer do Estado de São Paulo / São Paulo / SP / Brazil

Hospital Erasto Gaertner / Curitiba / PR / Brazil

CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS / Porto Alegre / RS / Brazil

São Camilo Oncologia / São Paulo / SP / Brazil

Hospital de Base de São José do Rio Preto / São José do Rio Preto / SP / Brazil

Liga Norte Riograndense / Natal / RN / Brazil

A Beneficência Portuguesa / São Paulo / SP / Brazil

Oncoclínicas / Rio de Janeiro / RJ / Brazil